¹Product-Related Research, Bayer HealthCare, Wuppertal, Germany

Correspondence: Dr E Bischoff, Product-Related Research, Bayer HealthCare, Aprather Weg 18a, Wuppertal 42096, Germany. E-mail: erwin.bischoff@bayerhealthcare.com

Received 13 February 2007; Revised 10 May 2007; Accepted 25 May 2007; Published online 12 July 2007.

Abstract

The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than 40 million men worldwide have been successfully treated with these compounds. The safety and high tolerability of PDE5 inhibitors make them an attractive tool to investigate further physiological functions of PDE5, for example the modulation of intracellular cyclic GMP (cGMP) pools. As cGMP is a key component of intracellular signaling this may provide novel therapeutic opportunities beyond ED even for indications in which chronic administration is necessary. The approval of sildenafil for the treatment of pulmonary hypertension in 2005 was a notable success in this area of research. A number of other potential new indications are currently in various phases of preclinical research and development. In recent years, extensive but very heterogeneous information has been published in this field. The aim of this review is to summarize existing preclinical and clinical knowledge and critically discuss the evidence to support potential future indications for PDE5 inhibitors.